Good
Mostly Aligned
Patient Risk:
Low
Summary
Most acute-treatment vs non-preventive framing is aligned with the label. Several statements are broadly inferential (e.g., “provided information does not indicate…timeline…”) and some omissions limit confidence because key label sections (contraindications/boxed warnings/detailed onset and safety limits) were not explicitly evaluated against the AI response.
Category Scores
Accurate Statements
Zavzpret (zavegepant) is used to treat acute migraine attacks.
Supported by 1 INDICATIONS AND USAGE: “ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults.”
Zavzpret is meant to stop migraine pain and other symptoms once a migraine starts.
Supported in concept by 1 INDICATIONS AND USAGE (acute treatment) and 14 CLINICAL STUDIES describing acute efficacy endpoints (e.g., pain freedom and MBS freedom at 2 hours).
The provided information does not indicate that Zavzpret is approved or intended to prevent migraines between attacks.
Supported/consistent with 1 INDICATIONS AND USAGE: “Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.”
Zavzpret is positioned as an on-demand option for migraine attacks rather than a preventive medicine.
Consistent with 1 INDICATIONS AND USAGE (acute treatment) and “Limitations of Use” (not indicated for preventive treatment).
Unsupported Statements
The provided information does not include onset timing for symptom relief for Zavzpret, so the exact timeline for stopping migraines is not stated.
The label excerpt provided includes a pharmacokinetic peak concentration timing (~30 minutes after a dose), and does not demonstrate that symptom-onset/relief timeline is absent from the label. The claim about missing symptom-relief onset timing is therefore not verifiable from the provided excerpts.
Contradictions
Important Omissions
Dose regimen constraints and safety limits (e.g., max 10 mg/24 hours; single-spray dosing; safety of treating >8 migraines/30 days) were not addressed despite being central to “how it is used.”
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The main clinical-intent statements (acute treatment vs not preventive) align with the label. The main issue is an unverifiable inference about missing onset timing, and omission of dose-limit/safety-limit details.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Overreaching inference regarding absence of symptom-relief onset timing in the label excerpts.
Suggested Improvement
Avoid stating that the label does not provide onset timing; instead, cite the label’s acute efficacy timing endpoints (e.g., outcomes measured at 2 hours) if discussing timeline.